TCM
NVO

Traynor Capital Management’s Novo Nordisk NVO Stock Holding History

Traynor Capital Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.32M Buy
27,500
+6,000
+28% +$258K 0.06% 120
2026
Q1 		$790K Buy
21,500
+20,000
+1,333% +$948K 0.05% 134
2025
Q4 		$76.3K Sell
1,500
-24,500
-94% -$1.25M ﹤0.01% 336
2025
Q3 		$1.44M Buy
+26,000
New +$1.52M 0.08% 98

Other funds holding NVO

SRIM
Saratoga Research & Investment Management Saratoga, California $1.83B AUM 18.41% 1-Year Est. Return
MG
Markel Group Glen Allen, Virginia $13.1B AUM 15.62% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
AIIMS
Analyst IMS Investment Management Services Tel-Aviv, Israel $4.3B AUM 37.33% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
QI
QV Investors Calgary, Alberta, Canada $1.3B AUM 31.14% 1-Year Est. Return
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Traynor Capital Management's NVO Position: Q2 2026 in Review

Traynor Capital Management reduced its Novo Nordisk (NVO) stake by 38% in Q2 2026, selling an estimated $6.41M and leaving 247,912 shares worth $11.9M. The position accounts for 0.55% of the portfolio, ranked #38.

Traynor Capital Management first reported a position in NVO in Q4 2014 and has held it in 47 quarters since. The position peaked at $42.2M in Q2 2024. 580 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Traynor Capital Management held 247,912 shares of Novo Nordisk worth $11.9M as of Q2 2026.
  • Traynor Capital Management sold 149,263 Novo Nordisk shares in Q2 2026, an estimated $6.41M.
  • Novo Nordisk made up 0.55% of Traynor Capital Management's portfolio in Q2 2026, its #38 holding.
  • Traynor Capital Management first reported a position in Novo Nordisk in Q4 2014 and has held it in 47 quarters since.
  • Traynor Capital Management's Novo Nordisk position peaked at $42.2M in Q2 2024.
  • 580 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Traynor Capital Management's 13F filing for Q2 2026, filed 22 Jul 2026.